Neuraxpharm Buys Glenmark’s Polish CNS Assets
Glenmark’s Jacek Sawicki Becomes Neuraxpharm’s Poland Manager
Executive Summary
Neuraxpharm has struck a deal to acquire Glenmark’s CNS portfolio in Poland. As part of the agreement, Glenmark’s Jacek Sawicki has been named as general manager of Neuraxpharm Polska and will lead a business that now incorporates Glenmark’s CNS commercial team.
You may also be interested in...
Neuraxpharm Snapped Up By Private Equity In Europe’s Largest Deal
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Asia Deal Watch: Daiichi Sankyo Pays $200m To Ultragenyx For AAV Technology Access
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
Neuraxpharm Targets Austria With Easypharm Deal
Neuraxpharm has opened a unit in Austria after snapping up local consumer healthcare specialist Easypharm.